Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2011

Liao S-, Rodgers WH, Kauderer J, Bonfiglio TA, Darcy KM, Carter R, et al. Carbonic anhydrase IX (CA-IX) and high-risk human papillomavirus (H-HPV) as diagnostic biomarkers of cervical dysplasia/neoplasia in Japanese women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) Study. Br J Cancer. 2011;104(2):353-60.

Mosquera J-, Dal Cin P, Mertz KD, Perner S, Davis IJ, Fisher DE, et al. Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas. Diagn Mol Pathol. 2011;20(3):129-37.

Oo ML, Chang S-, Thangada S, Wu M-, Rezaul K, Blaho V, et al. Engagement of S1P₁-degradative mechanisms leads to vascular leak in mice. J Clin Invest. 2011;121(6):2290-300.

Seidman JD, Yemelyanova A, Zaino RJ, Kurman RJ. The fallopian tube-peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol. 2011;30(1):4-11.

Moscat J, Diaz-Meco MT. Feedback on fat: p62-mTORC1-autophagy connections. Cell. 2011;147(4):724-7.

Hunt BJ, Wu X-, de Laat B, Arslan AA, Stuart-Smith S, Rand JH. Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. Am J Obstet Gynecol. 2011;205(5):485.e17-23.

Riera L, Lasorsa E, Bonello L, Sismondi F, Tondat F, Di Bello C, et al. Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. Leuk Lymphoma. 2011;52(9):1742-50.

Magro CM, A Crowson N. Folliculotropic T-cell lymphocytosis as a distinct form of pilotropic T-cell dyscrasia. Am J Clin Pathol. 2011;135(2):221-9.

Marvin J, Swaminathan S, Kraker G, Chadburn A, Jacobberger J, Goolsby C. Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML. Blood. 2011;117(15):e120-30.

Koon HB, Fingleton B, Lee JY, Geyer JT, Cesarman E, Parise RA, et al. Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr. 2011;56(1):64-8.